BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Hu YM, Mei Q, Xu XH, Hu XP, Hu NZ, Xu JM. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. World J Gastroenterol 2006; 12(29): 4750-4753 [PMID: 16937451 DOI: 10.3748/wjg.v12.i29.4750]
URL: https://www.wjgnet.com/1007-9327/full/v12/i29/4750.htm
Number Citing Articles
1
Ping-Huei Tseng, Yi-Chia Lee, Han-Mo Chiu, Hsiu-Po Wang, Jaw-Town Lin, Ming-Shiang Wu. A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 GenotypesJournal of Clinical Gastroenterology 2009; 43(10): 920 doi: 10.1097/MCG.0b013e3181960628
2
Alia Dadabhai, Frank K Friedenberg. Rabeprazole: a pharmacologic and clinical review for acid-related disordersExpert Opinion on Drug Safety 2009; 8(1): 119 doi: 10.1517/14740330802622892
3
Ayelet Lenz, Gal Lenz, Hsun Teresa Ku, Kevin Ferreri, Fouad Kandeel, Nigel Irwin. Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitroPLOS ONE 2019; 14(8): e0221456 doi: 10.1371/journal.pone.0221456
4
He-Jian Zhang, Xue-Hui Zhang, Jie Liu, Lu-Ning Sun, Yi-Wen Shen, Chen Zhou, Hong-Wen Zhang, Li-Jun Xie, Juan Chen, Yun Liu, Yong-Qing Wang. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitorsPharmacological Research 2020; 152: 104606 doi: 10.1016/j.phrs.2019.104606
5
Deepak Babu, Anwita Mudiraj, Neera Yadav, Chandrashekhar Y.B.V.K., Manas Panigrahi, Phanithi Prakash Babu. Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibitionCellular Oncology 2021; 44(4): 889 doi: 10.1007/s13402-021-00609-w
6
Akihiro Tajima, Kazuhito Koizumi, Kazuyoshi Suzuki, Naoko Higashi, Morio Takahashi, Tadahito Shimada, Akira Terano, Hideyuki Hiraishi, Hajime Kuwayama. Proton pump inhibitors and recurrent bleeding in peptic ulcer diseaseJournal of Gastroenterology and Hepatology 2008; 23(s2) doi: 10.1111/j.1440-1746.2008.05557.x
7
Shaojun Shi, Ulrich Klotz. Proton pump inhibitors: an update of their clinical use and pharmacokineticsEuropean Journal of Clinical Pharmacology 2008; 64(10): 935 doi: 10.1007/s00228-008-0538-y
8
Ivan N. Mefford, Ekpedeme U. Wade. Proton pump inhibitors as a treatment method for type II diabetesMedical Hypotheses 2009; 73(1): 29 doi: 10.1016/j.mehy.2009.02.010
9
Kohzo Takebayashi, Shintaro Sakurai, Tatsuhiko Suzuki, Kenichiro Hori, Tomoko Terasawa, Rika Naruse, Kenji Hara, Mariko Suetsugu, Takafumi Tsuchiya, Hiromi Aoki, Takashi Hamasaki, Hiroshi Shuutou, Toshihiko Inukai. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetesEndocrine Journal 2014; 61(10): 1031 doi: 10.1507/endocrj.EJ14-0208
10
S. Yi, H. Lee, S. B. Jang, H. M. Byun, S. H. Yoon, J.‐Y. Cho, I.‐J. Jang, K.‐S. Yu. A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteersAlimentary Pharmacology & Therapeutics 2017; 46(3): 337 doi: 10.1111/apt.14148
11
Manuel Román, Dolores Ochoa, Sergio Daniel Sánchez-Rojas, Maria Talegón, Rocio Prieto-Pérez, Ângela Rivas, Francisco Abad-Santos, Teresa Cabaleiro. Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazolePharmacogenomics 2014; 15(15): 1893 doi: 10.2217/pgs.14.141